Compare Gilead Sciences, Inc. (GILD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Twist Bioscience Corp — how do they compare? Gilead Sciences, Inc. trades at $131.5 (market cap $163.51B), while Twist Bioscience Corp trades at $92.63 (market cap $5.76B). The key difference: Gilead Sciences, Inc. is far larger — about 28.4× Twist Bioscience Corp's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| GILD | TWST | |
|---|---|---|
Market Cap | $163.51B | $5.76B |
Sector | Health | Health |
52-Week High | $155.80 | $102.88 |
52-Week Low | $108.22 | $24.16 |
Enterprise Value | $178.05B | $5.69B |
Dividend Yield | 2.49% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
